Both are excellent enterprises:

Lunan is a state-owned enterprise with a technological foundation, management more like a state-owned enterprise, and sufficient talent reserves;

Luo Xin relies on Starting from sales, there are more than 1,000 sales people, and the market concept is closer to a free economy;

Luo Xin was listed in Hong Kong, while Lunan chose to delist because Lunan really did not lack money.

Lu Nan is much larger than Luo Xin and has made greater contributions to the local area.

Personally, I think it is better to choose Luo Xin, as he has more training opportunities and his income is expected to be higher than Lunan.

Extended information:

1. Company profile of Shandong Luoxin Pharmaceutical Group Co., Ltd.:

1. Shandong Luoxin Pharmaceutical Group Co., Ltd. was listed by the state The Ministry of Science and Technology has recognized it as a "National Key High-tech Enterprise". The company has more than 30 production lines for powder injections, freeze-dried powder injections, water injections, solid preparations, chemical APIs, cephalosporin APIs, and oral cephalosporin series products. At present, there are more than a dozen dosage forms and more than 310 product specifications on the market, including 41 national-level new drugs, cephalosporins and other series of products, forming a one-stop production scale from the synthesis of starting raw materials to the preparation and packaging of finished products. It can produce 1 billion powder injections, 300 million freeze-dried powder injections, 500 million water injections, 2.5 billion tablets, 2 billion capsules, 300 million bags of granules, 80 million bags of dry suspensions, and cephalosporins annually. 300 tons of bacteriocin APIs and 100 tons of other chemical APIs.

2. The company adheres to the strategy of "promoting the enterprise through science and technology" and actively cooperates with major universities and scientific research institutions across the country. With Shenyang Pharmaceutical University as the scientific research support, the company has established "Shenyang Pharmaceutical University Luo Xin Pharmaceutical" "Shenyang Pharmaceutical University Luoxin Pharmaceutical Mobile Workstation", "Shenyang Pharmaceutical University Luoxin Pharmaceutical Teaching and Training Base", "Shenyang Pharmaceutical University Luoxin Pharmaceutical Internship Base", "Shenyang Pharmaceutical University Luoxin Pharmaceutical Graduates Employment Base". The company's product Jinxin was included in the 2011 subject of the National "Major New Drug Creation" Science and Technology Major "Twelfth Five-Year Plan" Implementation Plan - Technical Transformation of Large Variety of Drugs, and the company's "Cefizopran Hydrochloride API and Injection" project was included in the 2010 Annual Shandong Province Torch Program. In 2010, the company was recognized as the "National Comprehensive New Drug R&D Technology Platform (Shandong) Industrialization Demonstration Enterprise", "The Second Batch of Innovative Pilot Enterprises in Shandong Province", "China Patented Shandong Star Enterprise", and has established a Shandong Province Freeze Dry powder injection drug engineering technology research center, provincial enterprise technology center. After review by the Ministry of Human Resources and Social Security and the National Postdoctoral Management Committee, the company was approved to establish a national postdoctoral research station, which provides a new way for the company to cultivate, attract and use high-level professional and technical talents, enhance research and development capabilities, and promote the construction of an innovation system. Wide spaces.

3. The company actively implements the strategy of using technology to create product brands, using famous brand products to increase corporate visibility, and using corporate visibility to drive product sales, laying a solid stamina and foundation for corporate development. In order to speed up the implementation of scientific and technological innovation, the company has increased its investment in science and technology and withdraws 5% of sales revenue as scientific research funds every year to speed up the implementation of scientific and technological innovation. The company is accelerating the implementation of more than 30 scientific research projects and more than 20 clinical verification projects. Among them, there are several new Class I drugs with independent intellectual property rights that have been implemented in preclinical and clinical trials. The company attaches great importance to the training and construction of a team of scientific and technological talents, and currently has 151 full-time scientific and technological talents, including 6 with doctorate degrees and 28 with master's degrees.

4. Luoxin Pharmaceutical’s various economic indicators rank at the forefront of the same industry, and it has achieved good economic and social benefits. Many of its products have won the "Science and Technology Progress Award", and the traditional Chinese medicine freeze-dried powder injection Fushi 22 products including Kelin have obtained national invention patent certificates, with patent protection for 20 years. The company has been rated as an "AAA①" honest enterprise by the Ministry of Commerce, and the "Luoxin" trademark has been recognized as a "well-known trademark in China" by the Trademark Office of the State Administration for Industry and Commerce. It has been awarded the honorary titles of "AAA-level credibility enterprise", "contract-abiding and credit-abiding enterprise", "civilized unit", "advanced unit in the pharmaceutical industry" and other honorary titles by the province and city for many times. Since 2006, the company has continuously entered the top 100 enterprises in China's pharmaceutical industry and the top ten most growing pharmaceutical companies in China. Luoxin Pharmaceutical's market network is radiating rapidly across the country. It has self-operated import and export rights. Its stock has been listed in Hong Kong in 2005. It has also taken a gratifying step in the development of foreign markets, bringing the company's development into a new stage. New mileage.

2. Introduction to Lunan Pharmaceutical Company

1. Lunan Pharmaceutical Group is a large national comprehensive pharmaceutical group that integrates the production, scientific research and sales of drugs, chemicals and biological products. , a national innovative enterprise and a key high-tech enterprise of the National Torch Plan. Its member companies include seven companies including Lunan Houpu Pharmaceutical Co., Ltd., Lunan Beite Pharmaceutical Co., Ltd., Shandong New Era Pharmaceutical Co., Ltd., and Lunan New Era Pharmaceutical Co., Ltd. subsidiaries, ranked among the top 500 most competitive large enterprise groups in China, and ranked among the top 100 taxpayers in Dendong Province for eight consecutive years.

2. The group has the National Chiral Pharmaceutical Engineering Technology Research Center, the National Engineering Laboratory for High Efficiency Expression of Mammalian Cells, the National Key Laboratory of Chiral Pharmaceutical Chiral Technology, a National Enterprise Technology Center, and a postdoctoral fellow Scientific research platforms such as scientific research workstations and "Taishan Scholar" positions have established technical cooperation with more than 100 universities and scientific research institutes at home and abroad. The innovation ability of the enterprise technology center ranks at the forefront of the national pharmaceutical industry, and has won the "Best Domestic Pharmaceutical R&D Product Line" many times. "Top Ten Industrial Enterprises" title. He has won 1 second-class national technological invention award, 7 second-class national scientific and technological progress awards [19], and more than 100 provincial and municipal science and technology awards. It has applied for more than 1,000 international and domestic invention patents, and has obtained more than 500 authorized patents. The number of patents it holds ranks second in the domestic pharmaceutical industry. Among them, "A preparation of orlistat and its preparation method" won the 17th China Patent Gold Award; with more than 1,700 registered trademarks, the number of trademark registrations ranks first in Shandong Province, and has been identified as a "National Intellectual Property Operation Pilot Enterprise" and "Shandong Province Intellectual Property Demonstration Enterprise". The company has established a quality assurance system that is in line with international quality supervision concepts such as ICH, FDA, and EDQM. All dosage forms and varieties have passed the new national GMP certification, and the overall quality management level ranks among the top in the same industry nationwide.

3. Lunan Pharmaceutical Group has always adhered to the business purpose of "benefiting society and creating a better life", adhering to the enterprise spirit of "not afraid of difficulties, challenging difficulties and overcoming difficulties", and insisting on "taking reform as the driving force and taking With the development strategy of "market as the center and science and technology as the guide", it has now developed into a national large-scale comprehensive pharmaceutical group and has been awarded the titles of "National May 1st Labor Award", "National Model Employees' Home", "National Advanced Unit of Mass Sports" and other titles.

4. Lunan Pharmaceutical Group, which is in its prime and aspires to be global, is guided by "innovation-led and service-driven" and aims to "maintain the advantages of chemical pharmaceuticals, vigorously develop traditional Chinese medicines, and strengthen biopharmaceuticals" , achieve new and greater leaps on the international road of revitalizing national medicine and creating a century-old brand!